Theravance Biopharma Inc (NASDAQ:TBPH) Receives $35.00 Average Target Price from Analysts

Shares of Theravance Biopharma Inc (NASDAQ:TBPH) have been given an average recommendation of “Buy” by the eleven brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $35.00.

Several equities research analysts have commented on TBPH shares. ValuEngine upgraded Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Theravance Biopharma in a research note on Thursday, May 7th. Cowen began coverage on Theravance Biopharma in a research note on Wednesday, May 13th. They issued an “outperform” rating and a $42.00 target price on the stock. Zacks Investment Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating and set a $34.00 price objective on the stock. in a research note on Tuesday, May 12th. Finally, JPMorgan Chase & Co. began coverage on Theravance Biopharma in a research note on Tuesday, July 7th. They set an “overweight” rating and a $29.00 price objective on the stock.

NASDAQ TBPH traded down $0.77 during trading on Tuesday, hitting $19.42. The stock had a trading volume of 349,687 shares, compared to its average volume of 316,783. The company has a market capitalization of $1.23 billion, a PE ratio of -4.47 and a beta of 1.43. The company’s 50-day moving average price is $21.77 and its two-hundred day moving average price is $24.86. Theravance Biopharma has a 12 month low of $15.72 and a 12 month high of $31.54.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.07) by ($0.33). The business had revenue of $19.86 million during the quarter, compared to analysts’ expectations of $18.02 million. Sell-side analysts expect that Theravance Biopharma will post -3.87 EPS for the current year.

Several hedge funds have recently bought and sold shares of the stock. Peregrine Capital Management LLC acquired a new position in shares of Theravance Biopharma during the 2nd quarter worth approximately $9,487,000. First Quadrant L P CA acquired a new position in shares of Theravance Biopharma during the 2nd quarter worth approximately $81,000. State Street Corp increased its holdings in shares of Theravance Biopharma by 10.0% during the 1st quarter. State Street Corp now owns 1,055,268 shares of the biopharmaceutical company’s stock worth $24,387,000 after acquiring an additional 95,704 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Theravance Biopharma by 5.8% during the 1st quarter. Royal Bank of Canada now owns 25,081 shares of the biopharmaceutical company’s stock worth $580,000 after acquiring an additional 1,365 shares during the last quarter. Finally, Orbimed Advisors LLC acquired a new position in shares of Theravance Biopharma during the 1st quarter worth approximately $4,889,000. 80.77% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Featured Story: Cost of Capital

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.